Description
Cabozantinib Tablets Introduction to
Cabozantinib Tablets 20 mg is an active ingredient that acts as an antineoplastic drug. This medication belongs to the class known as tyrosine kinase inhibitors. Doctors use it to treat advanced kidney cancer and locally advanced or metastatic differentiated thyroid cancer in adults.
They also use it to treat liver cancer when Sorafenib, another anticancer medicine, no longer works. For advanced kidney cancer, this medicine is usually combined with Nivolumab. It is not recommended for individuals younger than 18 years.
Do not consume Cabozantinib 20 mg if you are allergic to it and its other ingredients. Inform your physician if you have liver disease, inflammatory bowel disease, high blood pressure, heart disease, or diarrhea.
Uses of Cabozantinib Tablet
- Advanced renal cell carcinoma
- Liver Cancer
- Differentiated thyroid cancer
Therapeutic Effects of Cabozantinib Tablet
It acts against a protein called receptor tyrosine kinases and interferes with cell signaling, ultimately stopping the growth and spread of cancer cells. Cabozantinib 40 mg alone or combined with Nivolumab is indicated.
Interaction of Cabozantinib Tablet with other drugs
Inform your doctor about any prescribed medications, over-the-counter medicines, nutritional or vitamin supplements, and herbal products you take or have taken before the treatment. Certain medications such as antibiotics, St, John’s Wort, Aliskiren and other medicine may interact with Cabozantinib 60 mg and can cause undesirable side effects.
More Information
- Keep out of sight and reach of pets and children
- Store protected from light at a temperature not exceeding 30°C.
How to consume
Take Cabozantinib as your physician advises. Typically, you will take this medicine once a day. Do not crush, chew, or open the medicine. Your physician will determine the correct dosage and duration based on your age, body weight, and disease condition. Stop taking this medicine only if your doctor advises you to stop.
Reviews
There are no reviews yet.